Parsaclisib(INCB050465)是一种高效、高选择性且具有口服活性的PI3Kδ抑制剂，其对PI3Kδ的IC50为1 nM，并对其他I类PI3K同工酶的选择性高达约20,000倍，在复发或难治性B细胞恶性肿瘤的研究中具有应用潜力。
/
-25~-15℃避光保存，有效期3年。
[1] Shin N, Stubbs M, Koblish H, Yue EW, Soloviev M, Douty B, Wang KH, Wang Q, Gao M, Feldman P, Yang G, Hall L, Hansbury M, O'Connor S, Leffet L, Collins R, Katiyar K, He X, Waeltz P, Collier P, Lu J, Li YL, Li Y, Liu PCC, Burn T, Covington M, Diamond S, Shuey D, Roberts A, Yeleswaram S, Hollis G, Metcalf B, Yao W, Huber R, Combs A, Newton R, Scherle P. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy. J Pharmacol Exp Ther. 2020 Jul;374(1):211-222. doi: 10.1124/jpet.120.265538. Epub 2020 Apr 28. PMID: 32345620.
